HMGB1 and allergic disease: However, pretreatment of HMGB1-activated DCs with sRAGE resulted in a significant reduction of neutrophil infiltration as well as IL-23 and IL-17 levels, further illuminating the putative role of HMGB1 signalling in DC-primed allergic diseases and demonstrating the potential of HMGB1 signalling blockade in DCs to control Th17 responses and neutrophilic airway inflammation.